Copertina

Real‐world comparative effectiveness of venetoclax‐obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Nilanjan Ghosh, Beenish S. Manzoor, Bita Fakhri, Nnadozie Emechebe, Hasan Alhasani, Alan Skarbnik, Dureshahwar Jawaid, Mazyar Shadman
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	British Journal of Haematology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Outcomes of Bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia in US veterans with severe renal dysfunction
di: Chenyu Lin, et al.
Pubblicazione: (2024)

Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients
di: Vincent Alcazer, et al.
Pubblicazione: (2024)

Treatment‐free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure
di: Mengyao Yuan, et al.
Pubblicazione: (2025)

Pericardial events associated with ibrutinib‐based therapies for chronic lymphocytic leukaemia in two landmark trials
di: Bita Fakhri, et al.
Pubblicazione: (2024)

Clinical profiles of chronic lymphocytic leukaemia patients with SF3B1 mutations: A single‐institution study
di: Bita Fakhri, et al.
Pubblicazione: (2025)

Matching‐adjusted indirect comparisons of efficacy and safety for zanubrutinib versus the combination of fixed‐duration venetoclax and ibrutinib in patients with treatment‐naïve chronic lymphocytic leukaemia
di: Talha Munir, et al.
Pubblicazione: (2025)

Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype
di: Andrea Serafin, et al.
Pubblicazione: (2025)

Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients
di: Camille Kockerols, et al.
Pubblicazione: (2024)

Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia
di: Tuan Hoang, et al.
Pubblicazione: (2025)

Measurable residual disease‐driven treatment in first‐line chronic lymphocytic leukaemia
di: M. S. Davids, et al.
Pubblicazione: (2024)

Potential impact of NOTCH1 activation on venetoclax sensitivity in chronic lymphocytic Leukaemia: In vitro insights and clinical implications
di: Ming‐Yuan Gao, et al.
Pubblicazione: (2024)

A matching‐adjusted indirect comparison of survival outcomes with pirtobrutinib ( BRUIN ) versus standard of care ( SCHOLAR ‐2) in relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor
di: Georg Heß, et al.
Pubblicazione: (2025)

Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study
di: Anke Gerhardt, et al.
Pubblicazione: (2024)

Epigenetic dysregulation and therapeutic targeting of RET receptor tyrosine kinase in high‐risk KMT2A ‐rearranged acute myeloid leukaemia
di: Arundhati Chavan, et al.
Pubblicazione: (2025)

Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation
di: Francesca Perutelli, et al.
Pubblicazione: (2025)

Second primary malignancies in Asian chronic lymphocytic leukaemia patients: A Taiwan Cancer Registry Study
di: Yi‐Wei Lee, et al.
Pubblicazione: (2026)

Safety and efficacy of spleen tyrosine kinase (Syk) inhibitors in the treatment of adults with persistent and chronic immune thrombocytopenia ( ITP ): A systematic review and meta‐analysis of randomised clinical trials
di: Mus'ab Theeb Mustafa, et al.
Pubblicazione: (2026)

Azacitidine–venetoclax in unfit acute myeloid leukaemia: One size does not fit all
di: Felicetto Ferrara
Pubblicazione: (2026)

The heart of VIALE‐A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia
di: Shyam A. Patel
Pubblicazione: (2024)

Chronic lymphocytic leukaemia extravaganza: Vacuolated lymphoma cells
di: Radu Chiriac, et al.
Pubblicazione: (2025)

Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents
di: Isla M. Johnson, et al.
Pubblicazione: (2024)

Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T‐cell therapy in Philadelphia chromosome‐positive acute lymphoblastic leukaemia
di: Tamer Othman, et al.
Pubblicazione: (2024)

Epigenetic silencing and pharmacological inhibition of EIF5A2 foster venetoclax sensitivity in acute myeloid leukaemia
di: Eva Crespo‐García, et al.
Pubblicazione: (2026)

Hypomethylating agent and venetoclax are effective salvage therapies in relapsed/refractory early T‐cell precursor acute lymphoblastic leukaemia
di: Vaibhav Agrawal, et al.
Pubblicazione: (2025)

Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia
di: Tony Marchand, et al.
Pubblicazione: (2024)

Patient‐reported health‐related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib–rituximab versus fludarabine–cyclophosphamide–rituximab
di: David J. Allsup, et al.
Pubblicazione: (2026)

Flow cytometry‐guided ex vivo drug sensitivity testing informs venetoclax‐based therapy in acute undifferentiated leukaemia
di: Lei Xu, et al.
Pubblicazione: (2026)

Salvage monotherapy with venetoclax after failure from a single course of standard induction chemotherapy for acute myeloid leukaemia
di: Pierre‐Yves Sansen, et al.
Pubblicazione: (2024)

The Mozart effect in chronic myeloid leukaemia
di: Jesper Stentoft
Pubblicazione: (2024)

An old leukaemia in young patients—Genetic characteristics of paediatric chronic myeloid leukaemia
di: Markus Metzler, et al.
Pubblicazione: (2025)

MN1::ETV6‐positive de novo T‐cell acute lymphoblastic leukaemia is sensitive to venetoclax: A case report
di: Xiang Zhang, et al.
Pubblicazione: (2024)

Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis
di: Barbora Weinbergerová, et al.
Pubblicazione: (2024)

Benchmarking spleen tyrosine kinase (Syk) expression in T‐ and NK ‐cell neoplasms: Implications for therapeutic targeting
di: Jing‐Ping Zhang, et al.
Pubblicazione: (2025)

γδ and αβ T‐cell large granular lymphocytic leukaemia have similar characteristics and outcomes
di: Rui Cui, et al.
Pubblicazione: (2024)

The chromosomal translocation t (1;6)(p35.3;p25.2), recurrent in chronic lymphocytic leukaemia, leads to RCC1 :: IRF4 fusion
di: Sandrine Jayne, et al.
Pubblicazione: (2024)

In the SARS‐CoV‐2 era, do we need to be afraid of obinutuzumab?
di: Joleen Choy, et al.
Pubblicazione: (2024)

Haematoidin in chronic myelomonocytic leukaemia during irregular treatment with hydroxycarbamide
di: Xiaohui Zhang, et al.
Pubblicazione: (2024)

Humoral and functional SARS ‐ CoV ‐2‐specific T‐cell responses elicited in chronic lymphocytic leukaemia patients with GEO ‐ CM04S1 a synthetic MVA ‐vectored COVID ‐19 vaccine
di: Sandra Ortega‐Francisco, et al.
Pubblicazione: (2025)

Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors
di: Mary Ann Anderson, et al.
Pubblicazione: (2025)

Clinical and molecular characteristics of paediatric mature B‐cell acute lymphocytic leukaemia and non‐Hodgkin lymphoma with bone marrow involvement: A joint study between the CCCG leukaemia and lymphoma groups
di: Jie Zhao, et al.
Pubblicazione: (2025)